Poxel Announces the Approval of a Prospectus for the Listing of New Shares on Euronext Paris
30 Juni 2023 - 7:30AM
Business Wire
Regulatory News:
POXEL SA (Euronext: POXEL – FR0012432516), a clinical stage
biopharmaceutical company developing innovative treatments for
chronic serious diseases with metabolic pathophysiology, including
non-alcoholic steatohepatitis (NASH) and rare metabolic disorders,
announces that the Autorité des Marchés Financiers (AMF) approved
today a Prospectus for the admission of new shares of the Company
that have been and may further be issued upon exercise of bonds
redeemable in shares (ORA) or bonds redeemable in new or existing
ordinary shares (ORANE) that already been issued or that may
further be issued pursuant to the financing agreements entered into
with IRIS, respectively on August 5, 2022 and March 22, 2023.
The Prospectus has been published to enable the admission on
Euronext Paris of these new shares of the Company when their number
will exceed 20% of the number of existing ordinary shares of the
Company as from the date of the issuance of the new shares that
occurred upon the first redemption of bonds redeemable in shares
(ORA) on August 9, 2022.
The Prospectus approved by the AMF under number 23-252 consists
of:
- the 2022 Universal Registration Document of the Company filed
with the AMF on April 28, 2023 under number D.23-0393 (the
“URD”),
- the amendment to the 2022 URD filed with the AMF on June 29,
2023 under number D.23-0393-A01,
- this Securities Note, and
- the Prospectus summary (included in this Securities Note).
This press release and the information it contains do not, and
will not, constitute an offer to subscribe for or sell, nor the
solicitation of an offer to subscribe for or buy, any securities of
the Company in any jurisdiction.
Copies of the Prospectus are available free of charge on the
website of the Company (www.poxelpharma.com) and the AMF
(www.amf-france.org) and at the registered office of the Company,
259/261 Avenue Jean Jaurès – Immeuble le Sunway – 69007 Lyon,
France.
About Poxel SA
Poxel is a clinical stage biopharmaceutical company
developing innovative treatments for chronic serious diseases
with metabolic pathophysiology, including non-alcoholic
steatohepatitis (NASH) and rare disorders. For the treatment of
NASH, PXL065 (deuterium-stabilized R-pioglitazone) met its
primary endpoint in a streamlined Phase 2 trial (DESTINY-1). In
rare diseases, development of PXL770, a first-in-class
direct adenosine monophosphate-activated protein kinase (AMPK)
activator, is focused on the treatment of adrenoleukodystrophy
(ALD) and autosomal dominant polycystic kidney disease (ADPKD).
TWYMEEG® (Imeglimin), Poxel’s first-in-class product that
targets mitochondrial dysfunction, is marketed for the treatment of
type 2 diabetes in Japan by Sumitomo Pharma and Poxel expects to
receive royalties and sales-based payments. Poxel has a strategic
partnership with Sumitomo Pharma for Imeglimin in Japan, China, and
eleven other Asian countries. Listed on Euronext Paris, Poxel is
headquartered in Lyon, France, and has subsidiaries in Boston, MA,
and Tokyo, Japan.
For more information, please visit: www.poxelpharma.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230629000499/en/
Investor relations / Media
Aurélie Bozza Investor Relations & Communication Senior
Director aurelie.bozza@poxelpharma.com +33 6 99 81 08 36
Elizabeth Woo Senior Vice President, Investor Relations &
Communication elizabeth.woo@poxelpharma.com
NewCap Emmanuel Huynh or Arthur Rouillé poxel@newcap.eu +33 1 44
71 94 94
Poxel (EU:POXEL)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Poxel (EU:POXEL)
Historical Stock Chart
Von Mai 2023 bis Mai 2024